B8FK Biofrontera AG

XETRA · DE · Healthcare · Drug Manufacturers - Specialty & Generic · biofrontera.com

3.680EUR+9.20%Mkt Cap: 24.31M $P/E: —3d ago

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States…

Industry Peers

Drug Manufacturers - Specialty & Generic

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

$57.06BUSD

TEVA

Teva Pharmaceutical Industries Limited Ordinary Shares

$46.10BUSDP/E 65.9

HLN

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Zoetis Inc. Class A Common Stock

$28.80BUSDP/E 11.4

UTHR

United Therapeutics Corporation - Common Stock

$23.23BUSDP/E 19.4

VTRS

Viatris Inc. - Common Stock

$20.22BUSD

SOBI

Swedish Orphan Biovitrum AB (publ)

$14.14BUSDP/E 110.6

NBIX

Neurocrine Biosciences, Inc. - Common Stock

Elanco Animal Health Incorporated Common Stock

$11.06BUSD

RDY

Dr. Reddy's Laboratories Ltd Common Stock

Amneal Pharmaceuticals, Inc. - Class A Common Stock

$7.07BUSDP/E 42.3

ALKS

Alkermes plc - Ordinary Shares

$7.00BUSDP/E 109.9

HIMS

Hims & Hers Health, Inc. Class A Common Stock

$6.77BUSD

LNTH

Lantheus Holdings, Inc. - Common Stock

$6.53BUSDP/E 23.9

KNSA

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

$5.83BUSDP/E 76.6

INDV

Indivior Pharmaceuticals, Inc. - Common Stock

$4.21BUSDP/E 12.8

Key Statistics

Company

Market Cap24.31M USD

Enterprise Value18.24M USD

Revenue (TTM)17.35M USD

Gross Profit11.86M USD

Net Income (TTM)-4.31M USD

Revenue/Share2.64 EUR

Last Price3.680 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees73

CountryDE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

ISINDE000A4BGGM7

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA8.11

EV/Revenue1.05

P/S1.40

P/B1.09

EPS (TTM)-1.24

EPS (Forward)—

52W Range

2.22099% of range3.700

52W High3.700 EUR

52W Low2.220 EUR

Profitability

Gross Margin82.71%

Oper. Margin26.88%

EBITDA Margin12.97%

Profit Margin-30.06%

ROE-26.60%

ROA-19.21%

Growth

Revenue Growth78.20%

Earnings Growth—

Cash Flow & Leverage

Operating CF-4.78M USD

CapEx (TTM)55.43K USD

FCF Margin—

FCF Yield—

Net Debt-5.95M USD

Net Debt/EBITDA-2.64

Balance Sheet

Debt/Equity0.00

Current Ratio3.60

Quick Ratio2.74

Book Value/Sh3.37 EUR

Cash/Share1.18 EUR

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 EUR

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Splits

Last Split1:21

Split DateMay 14, 2024

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.6.08M

Float1.39M

Insiders27.00%

Institutions0.00%

Technical

SMA 502.676 (+37.5%)

SMA 2002.541 (+44.8%)

Beta—

S&P 52W Chg14.58%

Avg Vol (30d)942

Avg Vol (10d)5.59K

Technical Indicators

RSI (14)75.3

MACD0.2723

MACD Signal0.1383

MACD Hist.+0.1340

BB Upper3.708 EUR

BB Middle2.691 EUR

BB Lower1.674 EUR

BB Width75.58%

ATR (14)0.2128 EUR

Vol Ratio (20d)3.22x